News

Xihong Biopharma Obtains NMPA Class Ⅲ Certificate for PLLA Microparticle Filler Injection

2025-07-16

The registration certificate of the Class Ⅲ medical device, Poly-L-lactic Acid Microparticle Filler Injection (the “Product”), has been approved by the National Medical Products Administration of China (NMPA), which marks a significant milestone for Xihong Biopharma in the regenerative product field, further expanding its consumer healthcare product portfolio.

MORE DETAILS

Xihong Biopharma With SoYoung Enter Shape the Future of Regenerative Anti-Aging Medicine

2023-07-06

The parties have entered into a 10-year exclusive master distribution agreement covering two advanced aesthetic products: the Sodium Hyaluronate Injectable Complex Solution and a new-generation Injectable PLLA Microsphere Facial Filler.

MORE DETAILS

Xihong Biopharma Grants Exclusive License to CMS for Injectable PLLA Filler

2025-07-10

The injectable poly-L-lactic acid (PLLA) microsphere filler is classified as a Class III medical device and is currently undergoing registrational clinical trials in China. The product utilizes a patented microsphere fabrication process, resulting in uniformly shaped microspheres with even subcutaneous distribution and outstanding clinical performance.

MORE DETAILS

Xihong Biopharma Wraps Up a Successful Showcase at AMWC 2025 Monaco

2025-03-29

Xihong Biopharma showcased its regenerative medicine solutions—combining advanced science, innovative manufacturing, and global partnerships. As a leading innovator from China, Xihong impressed attendees with its deep expertise and comprehensive portfolio in regenerative aesthetics.

MORE DETAILS